Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

98 results about "Membranous nephropathy" patented technology

Membranous nephropathy (MEM-bruh-nus nuh-FROP-uh-thee) occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become inflamed and thickened.

Application of ADAM10 or ADAM17 in preparation of medicine for preventing / treating membranous nephropathy

The invention discloses application of ADAM10 or ADAM17 serving as a target spot in preparation of a medicine for preventing / treating membranous nephropathy and application of an ADAM10 or ADAM17 inhibitor in preparation of the medicine for preventing / treating membranous nephropathy. The invention finds that ADAMs mediate the deposition process of immune complexes of autoantigens such as PLA2R1 of membranous nephropathy, and enzyme digestion of podocytes to transmembrane autoantigen proteins such as PLA2R can be inhibited by performing targeted intervention on the activity of ADAMs, especially the activity of ADAM10 and ADAM17, so that immune complexes deposited in glomerulus are reduced, the podocyte damage of membranous nephropathy is improved, and the therapeutic effect is achieved.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Method for constructing differential diagnosis model of lupus nephritis and membranous nephropathy

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.
Owner:BEIJING HOSPITAL

Method and system for predicting membranous nephropathy based on machine learning

The invention discloses a method and system for predicting membranous nephropathy based on machine learning, and relates to the technical field of medical diagnosis and treatment, and the method comprises the steps: collecting multi-source heterogeneous data of a patient; preprocessing the multi-source heterogeneous data, constructing a mapping relation between the traditional Chinese medicine syndrome type and the molecular biomarker, and generating a traditional Chinese and western medicine fusion feature matrix; screening a feature subset related to membranous nephropathy prediction from the traditional Chinese and western medicine fusion feature matrix; constructing a membranous nephropathy multi-level prediction framework according to the feature subset, and training each prediction model in the framework; and applying the trained and optimized membranous nephropathy multi-level prediction framework to the feature subset data of the new patient to generate a membranous nephropathy multi-dimensional prediction result. By establishing the Chinese and western medicine feature mapping relation, deep fusion of traditional Chinese medicine diagnosis and modern medical indexes is realized, and comprehensiveness and accuracy of disease diagnosis are improved.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Compositions and methods of treating lupus nephritis

The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
Owner:GENENTECH INC

Membrane nephropathy marker and application thereof

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Nucleic acids for inhibiting expression of complement factor b (CFB) in a cell

The invention relates to nucleic acid products that interfere with complement factor B (CFB) gene expression or inhibit its expression. The nucleic acids are preferably for use in the prophylaxis or treatment of complement associated diseases, disorders or syndromes, particularly C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), lupus nephritis, IgA nephropathy (IgA N), myasthenia gravis (MG), and primary membranous nephropathy.
Owner:SILENCE THERAPEUTICS GMBH

Marker for lupus nephritis and application thereof

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.
Owner:BEIJING HOSPITAL

Double-stranded siRNA analogue for inhibiting MASP2 expression as well as preparation method and application of double-stranded siRNA analogue

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Deep learning pathological image segmentation method for assisting membranous nephropathy diagnosis

The invention provides a deep learning pathological image segmentation method for assisting membranous nephropathy diagnosis, and belongs to the technical field of image segmentation analysis. The deep learning pathological image segmentation method specifically comprises the following steps: S1, manually marking an abnormal tissue region in a full-resolution pathological image by a professional physician; s2, adjusting a membranous nephropathy pathological image data set and carrying out local data labeling; marking abnormal areas according to professional physicians, and carrying out standardized data marking; s3, inputting the marked training set image into the SAM network model; and then initializing an image encoder, converting the abnormal tissue mask into an embedded vector by adopting a prompt encoder, fusing the embedded vector with image features, generating a segmentation mask and a confidence score by adopting a mask decoder, and finally obtaining a nephropathy pathological abnormal region segmentation map. According to the method, multi-scale labeling is carried out on abnormal tissues of membranous nephropathy, and a data set is finely adjusted by using a current relatively front SAM model architecture, so that the model is converged, considerable precision is achieved, and efficient and reliable technical support is provided for automatic analysis of membranous nephropathy pathological images.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Traditional Chinese medicine composition for treating nephropathy as well as preparation method and application thereof

PendingCN121550289AComponent separationUrinary disorderAnimal urine proteinChronic renal disease
The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.
Owner:GUIZHOU CHAOGE JIANHONG PHARM CO LTD

Method for obtaining information on efficacy of chemotherapy for patient with membranous nephropathy

Disclosed is a method for obtaining information on efficacy of chemotherapy for a patient with membranous nephropathy, the method comprising measuring CXCL13 in a biological sample collected from the patient with membranous nephropathy, in which the efficacy of chemotherapy for the patient with use of an anti-CD20 antibody drug is suggested by a measured result.
Owner:SYSMEX CORP

Kit for detecting human membranous nephropathy related indexes, method and application thereof

The present invention provides a kit, method and application for detecting human membranous nephropathy-related indicators. Through multiple mutation screenings of the coding nucleotide sequences of PLA2R antigen and THSD7A antigen, the most optimized sequences of PLA2R antigen and THSD7A antigen are obtained. The dialysis fluid formula in the preparation and purification processes of PLA2R antigen and THSD7A antigen, as well as the preservation fluid formula of PLA2R antigen and THSD7A antigen, are optimized. Highly pure PLA2R antigen and THSD7A antigen are prepared, and the problems of instability and batch-to-batch variation of PLA2R antigen and THSD7A antigen are solved to the greatest extent. The prepared kit can significantly improve the accuracy and sensitivity of detection, control batch-to-batch variation, and achieve rapid, accurate, simple and efficient detection of human membranous nephropathy-related indicators.
Owner:HANGZHOU HONGZHEN BIOTECHNOLOGY CO LTD +1

Kit for detecting PLA2R antibody in urine

The invention relates to the technical field of detection, and discloses a kit for detecting a PLA2R antibody in urine, which comprises a non-invasive urine sampling device, a pore plate detection module and a time-resolved fluorescence detection module, the non-invasive urine sampling device comprises a urine collecting cup, a collecting cup and a U-shaped siphon which are matched up and down; a spiral flow guide groove for guiding the collection cup is formed in the inner wall of the urine collection cup; the collecting cup is located at the bottom of the urine collecting cup, and scale marks are arranged on the side wall of the collecting cup; the inlet end of the U-shaped siphon is communicated with the side wall of the collecting cup and is higher than the bottom of the collecting cup, and the outlet end of the U-shaped siphon extends into the urine collecting cup. According to the kit, urine is used for replacing serum to serve as a PLA2R-IgG antibody detection sample, the problems that traditional serological detection cannot achieve real-time monitoring and is high in cost are solved through the simplified process of non-invasive sampling-time resolution detection, and a convenient solution can be provided for rapid screening of membranous nephropathy.
Owner:ZHEJIANG SCI-TECH UNIV

Diagnostic marker for ANCA-related vasculitis

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.
Owner:BEIJING HOSPITAL

Method and reagents for diagnosing membranous nephropathy

Provided are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.
Owner:EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA

A method for detecting urine small extracellular vesicle PLA2R1 membrane protein for distinguishing membranous nephropathy

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.
Owner:XIAMEN UNIV

Method for evaluating drug effect of rituximab on primary membranous nephropathy

The invention discloses a method for evaluating the drug effect of rituximab on primary membranous nephropathy. According to the method, an SNP (Single Nucleotide Polymorphism) site rs396991 of FCGR3A is mutated into AC or CC from wild type AA, and the 158th amino acid coded by the SNP site rs396991 is mutated into phenylalanine from valine; according to the invention, an iMLDR typing technology is adopted to detect an FGCR3A base mutation site, if rs396991 is AA type, the rs396991 is considered to be effective to an RTX drug, and if the rs396991 is detected to be AC type or CC type, the rs396991 is considered to be insensitive or ineffective to an RTX reaction; therefore, the rituximab can be used for effectively evaluating the drug effect of the rituximab on the primary membranous nephropathy.
Owner:NINGBO MEDICAL CENT LIHUILI HOSPITACL

Pla2r igg4 antibodies and uses thereof

The application provides a PLA2R monoclonal antibody and an ELISA kit comprising the antibody. Specifically, the application provides a monoclonal antibody which specifically binds to PLA2R, wherein the antibody only binds to non-reduced PLA2R antigen with a conformational epitope, does not bind to reduced PLA2R antigen, and does not bind to another antigen THSD7A of primary membranous nephropathy. An ELISA kit prepared based on the antibody can more efficiently and accurately detect primary membranous nephropathy than existing commercial kits.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Mama-based membranous nephropathy multi-mode pathological image quantitative analysis system and Mama-based membranous nephropathy multi-mode pathological image quantitative analysis method

The invention provides a Mama-based membranous nephropathy multi-mode pathological image quantitative analysis system and method, and belongs to the crossing field of biomedical engineering and artificial intelligence. The problems that in an existing membranous nephropathy diagnosis system, the diagnosis process is high in subjectivity, single-mode analysis is limited, lesion feature quantification is insufficient, and model calculation is complex are solved. According to the technical scheme, the system comprises an image preprocessing module, the image preprocessing module is in communication connection with a macroscopic lesion analysis module, a microstructure analysis module and a thickness quantification module, and the macroscopic lesion analysis module and the thickness quantification module are both in communication connection with a feature fusion and prediction module. The macroscopic lesion analysis module, the microstructure analysis module, the thickness quantification module and the feature fusion and prediction module are all in communication connection with the result visualization module, and multi-modal pathological image quantitative analysis of membranous nephropathy is realized; the method is applied to multi-mode pathological image analysis of membranous nephropathy.
Owner:TAIYUAN UNIVERSITY OF TECHNOLOGY

Application of ATP6V1D as marker for IgA nephropathy diagnosis and / or disease risk assessment

PendingCN120820715ADisease diagnosisBiological testingNephrosisMINIMAL CHANGE NEPHROPATHY
The invention provides application of ATP6V1D as an IgA nephropathy diagnosis and / or disease risk assessment marker, and belongs to the technical field of in-vitro diagnosis. The invention provides an application of ATP6V1D as a marker for IgA nephropathy diagnosis and / or disease risk assessment. The research finds that the ATP6V1D protein has different expressions in IgA nephropathy and healthy people, membranous nephropathy and slight lesion nephropathy, and can be used as a marker for IgA nephropathy diagnosis and / or disease risk assessment. The invention further provides a kit for detecting the ATP6V1D, and compared with an existing KM55 kit, the kit provided by the invention is low in price and high in detection sensitivity and specificity.
Owner:THE SECOND AFFILIATED HOSPITAL OF NANHUA UNIV

Microbial genetic markers for discriminating diabetic nephropathy and membranous nephropathy and use thereof

The application belongs to the technical field of kidney disease differential diagnosis, and particularly relates to a microbial gene marker for differentiating diabetic nephropathy and membranous nephropathy and application thereof. The application provides sufficient evidence for the differentiation and treatment of clinical diagnosis of diabetic nephropathy and pathological diagnosis of membranous nephropathy based on four microbial markers of Blautia, Akkermansia, Sphingomonas and Granulicatella.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Treatment of membranous nephropathy, IgG4-related disease, and antiphospholipid syndrome using the BTK inhibitor 2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazol[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)pyrazazin-1-yl]pent-2-enotrile

UndeterminedES3075571T3DiseasePhospholipid
This disclosure provides methods for treating a disease chosen from membranous nephropathy (MN), IgG4-related diseases, and antiphospholipid syndrome (APS) in a mammal using, for example, a therapeutically effective amount of the BTK inhibitor 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt thereof.
Owner:PRINCIPIA BIOPHARMA INC

Methods and materials for identifying and treating membranous nephropathy

This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and / or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and / or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Traditional chinese medicine composition for treating membranous nephropathy, preparation method therefor, and use thereof

PCT designated stageWO2025175743A1Urinary disorderConiferophyta medical ingredientsCytoplasmic VacuolationAstragalus mongholicus
Provided are a traditional Chinese medicine composition for treating membranous nephropathy, a preparation method therefor, and use thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 3-9 parts of Taxus chinensis, 9-12 parts of Curcuma zedoaria, 15-30 parts of Astragalus membranaceus, 6-12 parts of Panax notoginseng, and 10-20 parts of Gynostemma pentaphyllum. At the animal level, the traditional Chinese medicine composition can reduce proteinuria, regulate the lipid metabolism disorder, and protect the kidney. Furthermore, it is proved that the traditional Chinese medicine composition can alleviate the vacuolar degeneration of GBM or GBM thickening in experimental rats. Immunohistochemical analysis demonstrates that the formula can reduce the expression level of TGF-β1 in the renal interstitium, reduce the expression of ɑ-SMA and Col-IV collagen, reduce the deposition of ECM in the renal interstitium, and delay glomerulosclerosis and renal interstitial fibrosis.
Owner:SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL

20 (S)-PPD phospholipid solid dispersion as well as preparation method and application thereof

The invention relates to a composition and a preparation process of a 20 (S)-protopanoxadiol (20 (S)-protopanoxadiol, 20 (S)-PPD) phospholipid / mesoporous silicon solid dispersion, and belongs to the technical field of medicines. The invention provides a 20 (S)-PPD phospholipid / mesoporous silicon solid dispersion preparation. The preparation consists of 20 (S)-PPD, phospholipid, ethanol, a crystal inhibitor and a dispersing agent. The preparation disclosed by the invention is prepared by adopting a solvent evaporation method; the prepared 20 (S)-PPD phospholipid / meso-porous silicon solid dispersion is good in stability; the drug loading capacity is high, and the content of 20 (S)-PPD in the preparation can reach 40% or above; and the absolute bioavailability of oral administration is high and can reach 23.95%. After the preparation is orally taken, the injury of podocyte for maintaining the integrity of a glomerular filtration barrier can be remarkably relieved, and adult chronic nephrotic syndromes such as membranous nephropathy (MN) can be treated.
Owner:SHANDONG BIYUAN BIOMEDICAL CO LTD

Methods for treating primary membranous nephropathy

Provided here are methods of treating primary membranous nephropathy in a patient in need thereof, comprising administering to said patient a BTK inhibitor, e.g., (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof.
Owner:BEONE MEDICINES I GMBH

Traditional Chinese medicine composition for treating kidney micro abdominal mass and damp toxin exuberance type membranous nephropathy as well as preparation method and application of traditional Chinese medicine composition

The invention provides a traditional Chinese medicine composition for treating kidney micro abdominal mass and damp toxin exuberance type membranous nephropathy as well as a preparation method and application of the traditional Chinese medicine composition. The invention provides a traditional Chinese medicine composition for treating kidney micro abdominal mass and damp toxin accumulation type membranous nephropathy. The traditional Chinese medicine composition comprises the following raw materials: rhizoma dioscoreae nipponicae, euonymus alatus and oldenlandia diffusa in a mass ratio of 1: 0.6: 0.6. The preparation method adopts a water decoction extraction process and specifically comprises the following steps of soaking and water decoction, during water decoction, the water adding amount is 10-12 times of the amount of all the raw materials, the decoction time is 1.5-2 h, and the decoction frequency is 2-3 times. The traditional Chinese medicine composition for treating kidney microabdominal mass and damp toxin accumulation type membranous nephropathy provided by the invention has the advantages that the kidney microabdominal mass and damp toxin accumulation type membranous nephropathy can be effectively treated; the traditional Chinese medicine composition prepared by adopting the preparation method provided by the invention has higher safety, higher paste yield and higher dioscin content.
Owner:SHANXI PROVINCE CHINESE MEDICINE RESEARCH INSTITUTE

Application of BCMA-CD19 bispecific CAR-immune cell in treatment of membranous nephropathy

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in the treatment of membranous nephropathy. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating membranous nephropathy (MN); (ii) preparing a medicine for reducing the urine protein level; (iii) preparing a medicine for reducing the PLA2R antibody titer; (iv) preparing a medicine for improving the serum albumin level; and / or (v) preparing a medicine for improving the renal function eGFR level. The invention also provides a method for reducing urine protein level, reducing PLA2R antibody titer, increasing serum albumin level and / or increasing renal function eGFR level and a method for preventing and / or treating membranous nephropathy (MN) by using the BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or a CAR-immune cell thereof, or a pharmaceutical composition. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose that patients with high-risk, recurrent or refractory membranous nephropathy can continuously obtain clinical deep relief treatment.
Owner:FOSUN KITE BIOTECHNOLOGY CO LTD